Activates T-cell maturation and differentiation. Enhances NK cell activity, dendritic cell function, and antigen presentation. Modulates TH1/TH2 balance. Promotes thymic output.
Studies have administered: 1.6mg 2x weekly (approved dose in clinical use)
Decades of human clinical data. Approved for hepatitis B/C, AIDS, cancer adjunct therapy in multiple countries. COVID-19 trials showed mortality reduction in severe cases (multiple Chinese RCTs).
Extremely well-tolerated over decades of use; injection site reactions; rare transient flu-like symptoms
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Thymosin Alpha-1 — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat